Back to Top

Informing, inspiring, and advancing global innovation to support a healthy, sustainable future

For Immediate Release

Do Cytokines Have a Role in the Initiation and Progression of Breast Cancer?

Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, January 13, 2015—Emerging data on the role of inflammation and the immune system in the development, growth, and spread of breast tumors have focused increased attention on the role cytokines such asinterleukin and transforming growth factor-ß play in breast cancer initiation, protection, and metastasis. A comprehensive overview of this new knowledge and its potential to lead to novel therapeutic approaches is presented in a Review article in Journal of Interferon & Cytokine Research (JICR) from Mary Ann Liebert, Inc., publishers. The article is available free on the JICR  website until February 13, 2015.

The Role of Cytokines in Breast Cancer Development and Progression,” coauthored by Marcella Esquivel-Velázquez and colleagues from Universidad Nacional Autónoma de México (México City) and Instituto Nacional de Salud Pública (Morelos, Mexico), reviews the latest evidence to support a regulatory role for cytokines (proteins that mediate communication between cells of the immune system) in breast cancer and other cancer-related disorders. The article explores the link between cytokines, inflammation, and obesity, which is a significant risk factor for breast cancer. Other topics include the association between cytokines and blood vessel formation, breast cancer metastasis, immunosuppression and the ability of breast cancer cells to evade the immune system, and the potential role of cytokines as prognostic factors.

“This article provides a thorough discussion of the impact of inflammation and cytokine biology on many aspects of breast cancer and can serve as a helpful resource to find specific details regarding mechanisms and therapeutic potential,” says Journal of Interferon & Cytokine Research Co-Editor-in-Chief Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation.

About the Journal
Journal of Interferon & Cytokine Research (JICR), led by Co-Editors-in-Chief Ganes C. Sen, PhD, Chairman, Department of Molecular Genetics, Cleveland Clinic Foundation, and Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation, is an authoritative peer-reviewed journal published monthly online with Open Access options and in print that covers all aspects of interferons and cytokines from basic science to clinical applications. Journal of Interferon & Cytokine Research is an official journal of the International Cytokine & Interferon Society. Complete tables of content and a sample issue may be viewed on the JICR website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Viral Immunology, AIDS Research and Human Retroviruses, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com